Caplight Directory>Investors>Debiopharm Innovation Fund>Debiopharm-innovation-fund


Debiopharm Innovation Fund

Debiopharm Innovation Fund

Lausannedebiopharm.com

Overview

Debiopharm Innovation Fund is the corporate venture capital arm of Swiss biopharmaceutical company Debiopharm, which invests in digital health, smart data, and therapeutic companies with a focus on oncology and infectious diseases.

Year Founded

2006

AUM

$150M

Portfolio Companies

11

Investments

CompanyDateStageLead
ViewsMLApr 2026SeedCo-investor
RaidiumNov 2024SeedCo-investor
ViewsMLApr 2024SeedCo-investor
ConcrNov 2023SeedCo-investor
Altis LabsJun 2023SeedLead
View all investments

Sector & Stage Mix

Industry, funding stage, and valuation band breakdowns.

Premium
SeedSeries ASeries BGrowth

Unlock portfolio analytics

Sign up to view full sector, stage, and valuation breakdowns for this investor.

Investment Activity

Yearly cadence, pace, and funding raised over time.

Premium
2021
2022
2023
2024
2025
2026

Unlock portfolio analytics

Sign up to explore yearly investment trends and funding raised over time.

FAQ

Firmographic Details

HeadquartersLausanne
Year Founded2006
AUM$150M

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.